CL2020003272A1 - Nuevas formas cristalinas de 1-(4-{[6-amino-5-(4-fenoxi-fenil)-pirimidin-4-ilamino]-metil}-4-fluoro-piperidin-1-il)-propenona, formas de sal de la misma y procesos de obtención - Google Patents

Nuevas formas cristalinas de 1-(4-{[6-amino-5-(4-fenoxi-fenil)-pirimidin-4-ilamino]-metil}-4-fluoro-piperidin-1-il)-propenona, formas de sal de la misma y procesos de obtención

Info

Publication number
CL2020003272A1
CL2020003272A1 CL2020003272A CL2020003272A CL2020003272A1 CL 2020003272 A1 CL2020003272 A1 CL 2020003272A1 CL 2020003272 A CL2020003272 A CL 2020003272A CL 2020003272 A CL2020003272 A CL 2020003272A CL 2020003272 A1 CL2020003272 A1 CL 2020003272A1
Authority
CL
Chile
Prior art keywords
forms
propenone
ylamino
pyrimidin
piperidin
Prior art date
Application number
CL2020003272A
Other languages
English (en)
Inventor
Michael Lange
Clemens Kuehn
Tobias Schlueter
Werner Mederski
David Maillard
Edoardo Burini
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of CL2020003272A1 publication Critical patent/CL2020003272A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a una forma sólida de 1-(4-{[6-amino-5-(4-fenoxi-fenil)-pirimidin-4-ilamino]-metil}-4-fluoro-piperidin-1-il)-propenona (compuesto 1), o sales farmacéuticamente aceptables del mismo, útiles como inhibidores de BTK.
CL2020003272A 2018-06-19 2020-12-17 Nuevas formas cristalinas de 1-(4-{[6-amino-5-(4-fenoxi-fenil)-pirimidin-4-ilamino]-metil}-4-fluoro-piperidin-1-il)-propenona, formas de sal de la misma y procesos de obtención CL2020003272A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862686797P 2018-06-19 2018-06-19

Publications (1)

Publication Number Publication Date
CL2020003272A1 true CL2020003272A1 (es) 2021-05-07

Family

ID=67003464

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020003272A CL2020003272A1 (es) 2018-06-19 2020-12-17 Nuevas formas cristalinas de 1-(4-{[6-amino-5-(4-fenoxi-fenil)-pirimidin-4-ilamino]-metil}-4-fluoro-piperidin-1-il)-propenona, formas de sal de la misma y procesos de obtención

Country Status (12)

Country Link
US (2) US11878967B2 (es)
EP (1) EP3810590A1 (es)
JP (1) JP2021527685A (es)
KR (1) KR20210022674A (es)
CN (1) CN112313214A (es)
BR (1) BR112020025881A2 (es)
CA (1) CA3104191A1 (es)
CL (1) CL2020003272A1 (es)
IL (1) IL279485A (es)
MX (1) MX2020013321A (es)
SG (1) SG11202012595PA (es)
WO (1) WO2019243223A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240024314A1 (en) * 2020-01-08 2024-01-25 Telios Pharma, Inc. Methods of Treating Splenomegaly
MX2022008490A (es) * 2020-01-08 2022-10-13 Telios Pharma Inc Metodos de tratamiento de la esplenomegalia.
US20230295509A1 (en) 2020-06-10 2023-09-21 Merck Patent Gmbh Steerable antenna and method for heating and/or tempering of a steerable antenna
CN117986236A (zh) * 2022-11-07 2024-05-07 天津征程医药科技有限公司 氘代的嘧啶衍生物以及包含该化合物的药物组合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201801668WA (en) 2011-06-10 2018-03-28 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
SG11201408067YA (en) 2012-06-04 2015-01-29 Pharmacyclics Inc Crystalline forms of a bruton's tyrosine kinase inhibitor
CN103694241A (zh) 2013-11-27 2014-04-02 苏州晶云药物科技有限公司 Pci-32765的新晶型a及其制备方法
WO2016139588A1 (en) * 2015-03-03 2016-09-09 Dr. Reddy's Laboratories Limited Polymorphs of ibrutinib
CN107873029B (zh) * 2015-04-02 2020-09-01 拉蒂奥法姆有限责任公司 依鲁替尼与羧酸的共晶体
EP4014977A1 (en) * 2015-11-04 2022-06-22 Merck Patent GmbH Pyrimidine compounds with btk inhibitory activity for use in treating cancer
PT3377484T (pt) 2015-11-17 2023-12-14 Merck Patent Gmbh Métodos para tratamento de esclerose múltipla utilizando compostos de pirimidina e piridina com atividade inibidora de btk
US10464923B2 (en) * 2017-02-27 2019-11-05 Merck Patent Gmbh Crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-piperidin-1-yl)-propenone

Also Published As

Publication number Publication date
KR20210022674A (ko) 2021-03-03
JP2021527685A (ja) 2021-10-14
WO2019243223A1 (en) 2019-12-26
AU2019289628A1 (en) 2021-02-04
US20210261525A1 (en) 2021-08-26
EP3810590A1 (en) 2021-04-28
BR112020025881A2 (pt) 2021-03-23
SG11202012595PA (en) 2021-01-28
MX2020013321A (es) 2021-02-22
IL279485A (en) 2021-01-31
US20240132472A1 (en) 2024-04-25
CN112313214A (zh) 2021-02-02
US11878967B2 (en) 2024-01-23
CA3104191A1 (en) 2019-12-26

Similar Documents

Publication Publication Date Title
CL2020003272A1 (es) Nuevas formas cristalinas de 1-(4-{[6-amino-5-(4-fenoxi-fenil)-pirimidin-4-ilamino]-metil}-4-fluoro-piperidin-1-il)-propenona, formas de sal de la misma y procesos de obtención
MX2019010043A (es) Nuevas formas cristalinas de 1-(4-{[6-amino-5-(4-fenoxi-fenil)-pir imidin-4-ilamino]-metil}-piperidin-1-il)-propenona.
CL2019003086A1 (es) Compuestos de imidazo-piperidina fusionada como inhibidores de jak.
ECSP20025899A (es) Compuestos útiles para inhibir a cdk7
CO2022002637A2 (es) Proceso de fabricación de moduladores de cftr
AR111469A1 (es) Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma
DOP2020000109A (es) Derivado de amino-flocoropiperidina como inhibidor de quinasa
ECSP20035588A (es) Derivado de amino-metil piperidina como inhibidor de quinasa
UY35998A (es) 1-(3-(tert-BUTIL)1-(p-TOLIL)-1H-PIRAZOL-5-IL)-3-(4-((2-((6-ETILPIRAZIN-2-IL)AMINO)PIRIDIN-4-IL)METOXI)NAFTALEN-1-IL) UREA Y SUS SALES DERIVADAS FARMACÉUTICAMENTE ACEPTABLES, COMO INHIBIDORES DE P38 M AP QUINASA
NI202000092A (es) Compuestos
CL2020001752A1 (es) Derivado de oxi-fluoropiperidina como inhibidor de quinasa.
CL2015002309A1 (es) Proceso de fabricacion de vortioxetina.
CL2020000217A1 (es) Inhibidores de ror gamma.
CO2018007008A2 (es) "procesos mejorados para la preparación de osimertinib (azd9291) o una sal del mismo y "azd9291 anilina" o una sal del mismo"
MY193239A (en) Novel b-lactamase inhibitors
CL2020000190A1 (es) Inhibidores de ror-gamma.
AR116951A1 (es) Sales cristalinas de un inhibidor de calicreína plasmática
BR112017016819A2 (pt) compostos de diaza-benzofluorantreno
PH12021550456A1 (en) Crystalline forms of a quinazole compound and its hydrochloride salts
DOP2019000194A (es) Derivados de pirrolotriazina como inhibidor de cinasas
MX2020004388A (es) Forma cristalina del inhibidor de alquinil piridina prolil hdroxilasa y metodo para preparar la misma.
AR110998A1 (es) Inhibidores de la tirosina cinasa de bruton
BR112017004694A2 (pt) composições farmacêuticas compreendendo alpelisibe
CO2019012594A2 (es) Proceso para la preparación de enantiómeros de pirlindol y sus sales
CO2019001139A2 (es) Síntesis de (s)-2-amino-4-metil-1-((r)-2-metiloxirano-2- il)-pentan-1-ona y sales farmacéuticamente aceptables de la misma